On March 14, the English edition of Nonclinical Evaluation Studies of Cellular and Gene Therapy Products, 2nd edition was unveiled at the "2026 Cell and Gene Therapy (CGT) Frontier Innovation & Clinical Translation Academic Conference and Document No. 818 Interpretation Seminar." SUN Yu, Associate General Editor of Tsinghua University Press--a co-organizer of the event, attended the ceremony and delivered a speech.
The editorial team and representatives from Tsinghua University Press
SUN Yu, in her address, noted that cell and gene therapy (CGT) represents a frontier in the biopharmaceutical field and a key strategic priority for China. Its standardized development relies on systematic academic guidance and practical support. The second edition of this book brings together the wisdom of numerous authoritative scholars; the editorial team's rigorous academic standards ensure the book's authority, scientific integrity, and practicality. She emphasized the importance of licensing the English edition rights to Elsevier. This project formally introduces China's advancements in this research area to the global scholarly landscape. It is both a meaningful exercise in international collaboration and a vital practice in building China's academic discourse. She further stated that Tsinghua University Press will continue to work with global scholars and institutions to promote high-quality Chinese academic works to the world.
SUN Yu, Associate General Editor of Tsinghua University Press, gives a speech
WANG Quanjun, the book's Editor-in-Chief and Chairman of the conference, stated that since the project began in 2020, the book has gained widespread recognition as an essential reference for domestic researchers. The licensing of English rights to Elsevier is a testament to the hard work of the editorial team and highlights the international attention focused on China's academic progress in CGT. He noted that this is not just the international distribution of a book, but a new starting point for Chinese scholars to engage and grow alongside global peers in the field of nonclinical evaluation.
WANG Quanjun, the book's Editor-in-Chief and Chairman of the conference, gives a speech
The successful licensing of this book's rights represents a major breakthrough for Chinese academic publishing in the life sciences. As a strategically emerging field, the technical standards and evaluation systems for CGT are directly linked to high-quality industrial development. This international release not only showcases China's academic strength in nonclinical evaluation, but also provides a "China Solution" for global peers, giving Chinese scholars a stronger voice in shaping global regulatory frameworks.
